Nebenwirkungen · Cancidas (previously Caspofungin MSD)
CANCIDAS 50 mg powder for concentrate for solution for infusion CANCIDAS 70 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7–8
HOS-109328 · Präparat HOS-093179
7 System Organ Common (≥1/100 to Uncommon (≥1/1,000 to <1/100) Not known Class <1/10) (cannot be estimated from available data) urinary disorders General disorders pyrexia, chills, infusion- pain, catheter site pain, fatigue, and site pruritus feeling cold, feeling hot, infusion administration site erythema, infusion site site conditions induration, infusion site pain, infusion site swelling, injection site phlebitis, oedema peripheral, tenderness, chest discomfort, chest pain, face oedema, feeling of body temperature change, induration, infusion site extravasation, infusion site irritation, infusion site phlebitis, infusion site rash, infusion site urticaria, injection site erythema, injection site oedema, injection site pain, injection site swelling, malaise, oedema Investigations blood potassium blood creatinine increased, red decreased, blood albumin blood cells urine positive, protein decreased total decreased, protein urine present, prothrombin time prolonged, prothrombin time shortened, blood sodium decreased, blood sodium increased, blood calcium decreased, blood calcium increased, blood chloride decreased, blood glucose increased, blood magnesium decreased, blood phosphorus decreased, blood phosphorus increased, blood urea increased, activated partial thromboplastin time prolonged, blood bicarbonate decreased, blood chloride increased, blood potassium increased, blood pressure increased, blood uric acid decreased, blood urine present, breath sounds abnormal, carbon dioxide decreased, immunosuppressant drug level increased, international normalised ratio increased, urinary casts, white blood cells urine positive, and pH urine increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T16:40:00Z · SHA-256 6dd11a424b362e655ce61e4c49586bb6e658af1133d504982e2602258f5f83f7 · Passage 663c23001345aedc5c501beddb196cb566228d7cc6ce09c0f12c58b26b688477 · Zeichen 7203–11306 im Abschnitt